Breaking News

0 387
Foamix Pharmaceuticals Ltd FOMX Stock News

Foamix Pharmaceuticals Ltd (NASDAQ: FOMX)

Foamix Pharmaceuticals is having an incredibly rough start to the week in the pre-market hours today. After announcing the results from a clinical study that failed to meet its primary endpoint, the stock started to fall dramatically, prompting our partners at Trade Ideas to alert us to the downward movement. At the moment (8:25), FOMX is trading at $4.86 per share after a loss of $4.24 per share (46.59%) thus far today.





FOMX Phase 3 Trial Failure

As mentioned above, Foamix Pharmaceuticals is having an overwhelmingly rough start to the week in today’s pre-market trading. The declines are the result of failed clinical trials. In fact, the company released results from two Phase 3 trials surrounding the experimental treatment known as FMX101, which has been designed to treat moderate-to-severe acne.




In the release, we learned that while there was some positive news, when it comes to the key endpoint, the study was a failure. In fact the FOMX treatment performed well with regard to both co-primary endpoints in Trial 05, but in Trial 04, a key co-primary endpoint, the IGA success, was missed. As a result, investors reacted by sending the stock downward.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on FOMX. In particular, we’ll be watching for any news with regard to the company’s plans moving forward. We’ll continue to follow the news and bring it to you as it breaks!

Check Out What The Trading Community Is Saying On StockTwits!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

GNC Holdings Inc GNC Stock News

GNC Holdings (NYSE: GNC)

GNC Holdings is having a pretty good start to the trading session today as takeover rumors start to fly. As soon as the rumor started, the stock jumped, prompting our partners at Trade Ideas to alert us of the movement. At the moment (10:02), GNC is trading at $7.06 per share after a gain of $0.07 or 1% thus far today.





GNC Takeover Rumor

As mentioned above, GNC is having a strong time in the market, at least at the moment, thanks to rumors that the company will be taken over. The rumor suggest that JD.com is currently in the process of raising funds in order to make a bid for the company.

It’s important to keep in mind that at the moment, there is no confirmation surrounding the rumors. Not to mention that the source of the rumor is social media and impossible to track to the beginning.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to watch GNC closely to see if there is any validity to the rumors. However, we do not expect that this acquisition is going to happen. First and foremost, the two companies don’t sync well at all. That, on top of the fact that JD.com would have to raise funds in order to even make a bid simply doesn’t make sense. Sure, it was good for a nice quick pop in the stock, but don’t get your hopes up.

What Do You Think?

Do you think GNC will be taken over by JD.com? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 472
Ignyta Inc RXDX Stock News

Ignyta Inc (NASDAQ: RXDX)

Ignyta is having a strong time in the pre-market hours this morning after announcing that it is exploring strategic options with regard to one of its key products. As a result, the stock is headed upward, which caused our partners at Trade Ideas to alert us of the gains. At the moment (4:23), RXDX is trading at $9.20 per share after a gain of $0.30 per share or 3.37% thus far today.





RXDX To Explore Strategic Options Surrounding Taladegib

As mentioned above, Ignyta is having an incredibly strong start to the day in today’s pre-market hours. The gains are the result of an announcement the company made early on this morning with regard to taladegib. The company said that it is in the process of exploring strategic options surrounding the product. In the process, it has entered into an amended and restated license, development and commercialization agreement with Eli Lilly (LLY) for the taladegib oncology program.




The agreement with LLY that RXDX announced the amendment to today amends and restates the prior license, development and commercialization agreement that was signed on November 6, 2015. Taladegib is a highly potent, orally bioavailable small molecule hedgehog/shoothened antagonist. The treatment has achieved clinical proof of concept and has also been recommended to move forward to Phase 2.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching RXDX incredibly closely. In particular, we’re interested in the agreement with LLY and the ongoing work surrounding taladegib. Nonetheless, we’ll continue to follow the story closely and bring you any updates as they break!

What Do You Think?

Where do you think RXDX is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 698
Abbott Laboratories ABT Stock News

Mylan Br (NASDAQ: MYL) | Abbott Laboratories (NYSE: ABT)

Mylan is having a rough day in the market today, and for good reason. Early this morning, it was announced that Abbott Laboratories has made the decision to sell a large amount of shares, sending the stock tumbling. As a result of the declines, our partners at Trade Ideas alerted us of the movement. Currently (8:43), MYL is trading at $40.21 per share after a loss of $1.40 per share or 3.35% thus far today.





ABT Sells MYL Shares

As mentioned above, Mylan is having an incredibly rough start in the pre-market hours today after it was announced that Abbot Laboratories has made the decision to sell a large amount of shares. In fact, ABT sold 44 million MYL shares. The shares were sold at a price of $41.60 per share on March 23rd. So, why did ABT Sell?




Well, they never really planned on holding onto the shares. You see, a short while ago, ABT sold MYL its overseas developed market generic drug business to MYL for more than $5 billion in an all stock deal. At the time, the company said that it planed on using the proceeds from the deal to fund higher-return projects. Considering the 32% of its stake that it sold yesterday, it now has the funds to do just that. Nonetheless, ABT still owns quite a bit in MYL, which has grown 22% since the deal mentioned above.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ABT. In particular, we’re interested in learning more about the company’s plans for the proceeds generated through the sale of MYL shares. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks.

What Do You Think?

Where do you think ABT and MYL are headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Max Pixel]

0 591
PTC Therapeutics, Inc. PTCT Stock News

PTC Therapeutics, Inc. (NASDAQ: PTCT)

PTC Therapeutics is having a rough start to the day today in the pre-market hours and for good reason. The company has made the decision to withdrawal a regulatory application in Europe. As a result, investors started to dump the stock, leading to early morning declines and an alert from our partners at Trade Ideas. At the moment (8:11), PTCT is trading at $8.00 per share after a loss of $0.45 per share or 5.33% thus far today.





PTCT Withdrawals Regulatory Application

As mentioned above, PTC Therapeutics is having an incredibly rough time in the pre-market hours today after announcing that it has withdrawal a regulatory application. The application was submitted to the European Medicines Agency (EMA) a short while ago and surrounded the company’s experimental new drug, Translarna. Translarna was designed to treat patients with cystic fibrosis.

Unfortunately however, PTC Therapeutics submitted a letter to the EMA informing them that they would like to withdrawal the application. That letter is available to the public here. There were multiple reasons for the withdrawal, but of most importance is the fact that the EMA CHMP was concerned about renal toxicity issues as a key quote from the withdrawal letter points out…




The CHMP was also concerned about harmful effects on the kidneys seen in patients treated with Translarna. These side effects appeared to be due to the fact that Translarna may worsen the effects on the kidney of certain antibiotics given by injection, which are important in treating infections in patients with cystic fibrosis.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PTCT. In particular, we’re interested in learning the company’s planned next steps and more about other regulatory attempts surrounding translarna. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

What Do You Think

Where do you think PTCT is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 627
Xenon Pharmaceuticals Inc XENE Stock News

Xenon Pharmaceuticals Inc (NASDAQ: XENE)

Xenon Pharmaceuticals is having an overwhelmingly rough start to the day in the pre-market hours, and for good reason. The company released data from a clinical trial that didn’t match expectations. As a result, investor fear ensued, leading to the declines. Shortly after the news broke, our partners at Trade Ideas alerted us of the declines on the stock. Currently (8:04), XENE is trading at $5.75 per share after a loss of $4.10 per share or 41.62% thus far today.





XENE Phase II Trial Fails

As mentioned above, Xenon Pharmaceuticals is having an incredibly rough morning in the market today after announcing results from a recent Phase II clinical trial. The trial surrounded XEN801, a treatment designed for patients with moderate to severe acne. Unfortunately, it was announced that the company missed its primary efficacy endpoints with regard to the trial.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on XENE. In particular, we’re watching for any news associated with the company’s plans moving forward. Obviously, chances are that XEN801 will be out of the running here, but luckily that’s not the only treatment in the pipeline. Nonetheless, we’ll continue following the stock closely and bringing the news to you as it breaks!

What Do You Think?

Where do you think XENE is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 599
FireEye Inc FEYE Stock News

FireEye Inc (NASDAQ: FEYE)

FireEye is having an incredibly strong day in the market today. At the opening bell, the stock was already trading on dramatic gains, leading to an alert from our partners at Trade Ideas. Since then, the stock hasn’t seen much movement, but has held onto strong gains. At the moment (1:29), FEYE is trading at $12.37 per share after a gain of $0.88 per share or 7.66% thus far today.





Goldman Sachs Upgrades FEYE

As mentioned above, Goldman Sachs has made the decision to upgrade FireEye, leading to big gains in the value of the stock. The firm upgraded the stock from a Sell rating to a Buy rating, also increasing its price target on the stock. The price target has been increased from $10.00 to $15.00. In a statement, Goldman Sachs analyst, Gabriela Borges had the following to offer…

Street 2017 product revenue and billings estimates have been materially reset, with mix shift to recurring revenue occurring faster than we expected, and increased detail on the pricing model for Helix. We believe the introduction of Helix, an advanced analytics platform, addresses many of FireEye’s previous challenges by reducing total cost of ownership (TCO) by 33-50%, and streaming the company’s go-to-market under its new head of sales. As the new model comes into focus, we expect more consistent execution and FCF generation. Since being added to Americas Sell List on 11/22/16, FEYE is -12% vs. S&P 500 =7%.”




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on FEYE. In particular, we’re interested in watching as the company launches Helix to see just how beneficial the new product is to the books. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Max Pixel]

Tripadvisor Inc Common Stock TRIP Stock News

Tripadvisor Inc Common Stock (NASDAQ: TRIP)

Tripadvisor was off to a relatively normal day in the market today. That is, until minutes ago when the stock spiked in a big way, prompting our partners at Trade Ideas to send an alert about the growth. The gains seem to be the result of a rumor that’s surfacing. Nonetheless, the stock is trading at $42.20 per share after a gain of $0.80 per share or 1.93%.





PCLN Rumored To Be Taking TRIP Over

As mentioned above, Tripadvisor was having a relatively normal day in the market until a rumor broke just minutes ago, causing rocket-like upward movement. The rumor that broke is that Priceline may be acquiring the company relatively soon. However, we do not believe that there is any validity to the rumors.




While TRIP and PCLN would definitely sync up well together, the rumor just doesn’t seem to hold weight. There is no suggestion of what the price might be, nor has there been any reports of interest in this deal from either company as of late. This is the first we’re hearing of it, and the source is social media, making it nearly impossible to pin down the original source. All in all, things just aren’t adding up.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TRIP. In particular, we’re interested in learning more about the potential takeover by PCLN. Of course, we don’t believe that there’s any validity to the rumor, but we can’t see into the future. So, anything could happen. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 551
SuperValu Inc. SVU Stock News

SuperValu Inc. (NYSE: SVU)

SuperValu is having an incredibly strong day in the market today. At the open, the stock was already trading in the green and has only climbed from there. Ultimately, the cause of the gains is an upgrade. As soon as the upgrade happened, the stock started spiking upward, causing our partners at Trade Ideas to alert us of the gains. At the moment (12:01), SVU is trading at $3.73 per share after a gain of $0.39 per share or 11.68% thus far today.





SVU Upgraded By RBC

As mentioned above, SuperValu is having an incredibly strong day in the market today as the result of an upgrade. The upgrade came from RBC Capital, who made the decision to increase the rating on the stock from a Sector Perform to an Outperform. Of course, the upgrade let to a frenzy among investors, causing the stock to fly.




What Do You Think?

Where do you think SVU is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

LSC Communications Inc LKSD Stock News

LSC Communications Inc (NYSE: LKSD)

LSC Communications is having an incredibly strong day in the market, which is interesting as they just announced a secondary offering. Nonetheless, the secondary caused excitement, sending the stock up and prompting our partners at Trade Ideas to alert us of the gains. At the moment (11:32), LKSD is trading at $23.49 per share after a gain of $2.66 per share or 12.77% thus far today.





LKSD Announces Secondary Offering

As mentioned above, LSC Communications is having an incredibly interesting start to the day today after announcing a secondary offering. The company said it would be selling 6,242,082 shares of common stock at a price of $20.25 per share. The company also informed investors that it has given underwirters at 30-day option to purchase up to an additional 936,420 shares at the secondary pricing.




The interesting part in all of this is that the stock is actually climbing. In general, secondary offerings cause concerns with regard to dilution, leading to declines in the stock’s value, but that’s not the case with LKSD. This shows that the market sees a need for the money and expects that the funds raised through the offering will lead to stronger operations and better results. While this is a rarity in the market, it’s always nice to see.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on LKSD. In particular, we’re interested in learning more about the company’s plans with the money it is raising, and watching the company put the plan into action. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 3890
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...